Full Press Release Details
ProSense Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference
Israel, March 18, 2025 - IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"),
developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal,
today announced that it exhibited at the 19th Annual St. Gallen Breast Cancer Conference in in Vienna, Austria from March 12 -
15, 2025. Six studies of ProSense in breast cancer were accepted as peer-reviewed abstracts, presented as e-posters during
the conference, and are being published in the scientific journal, The Breast after the conference.
received a high level of interest at this prestigious breast cancer conference in Europe where our cryoablation system is gaining
increasing commercial traction driven by regulatory approval and a growing body of efficacy and safety data from third party studies,"
IceCure's Chief Executive Officer, Eyal Shamir commented. "Among the benefits of these investigator-initiated studies is
that each practitioner studies different patient populations in varied settings and circumstances, producing a breadth and depth of data
that would simply not be available even in the largest of company-sponsored global studies. We are grateful to the investigators as we
all aim toward the same goal of advancing women's health through innovation and collaboration."
following studies of ProSense were presented:
The ProSense Cryoablation System
is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses
the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions,
including breast, kidney, lung, and liver.
enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy,
transportable design and liquid nitrogen utilization, ProSense opens that door to fast and convenient office-based procedures
Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors
(benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology
is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The
Company's flagship ProSense system is marketed and sold worldwide for the indications cleared and approved to date
including in the U.S., Europe and China.
press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions or variations of such words
are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press
release when it discusses: the potential benefits of the cryoablation studies; the Company's aim towards advancing women's
health through innovation and collaboration; and the potential implications of the ProSense studies that were presented at the St. Gallen
International Breast Cancer conference. Historical results of scientific research and clinical and preclinical trials do not guarantee
that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause
actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include,
among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain
additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and
other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability
to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical
professionals about its products; political, economic and military instability in the Middle East, specifically in Israel;
as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December
31, 2023 filed with the SEC on April 3, 2024, and other documents filed with or furnished to the SEC which are available on
the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the
date of this release, except as required by law.